Literature DB >> 19371236

Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.

Viola Harde1, Ulrich Mrowietz.   

Abstract

Hidradenitis suppurativa is a chronic inflammatory skin disease featuring inflammatory nodules, fistulas and discharge of secretions in the intertriginous regions. Without therapy the disease is chronic and progressive. The most effective treatment is the radical wide excision of the affected areas. Systemic antibiotics, immunosuppressants, oral retinoids or antiandrogens have limited beneficial effects. TNF-alpha antagonists may represent a new therapeutic approach for patients suffering from severe hidradenitis suppurativa offering promising positive influence on the disease outcome. In contrast to infliximab and etanercept, there are only few reports describing the use of adalimumab in severe hidradenitis suppurativa. Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371236     DOI: 10.1111/j.1610-0387.2008.06918.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  7 in total

Review 1.  [Systemic treatment of moderate/severe hidradenitis suppurativa].

Authors:  A Pinter; U Mrowietz; T Volz
Journal:  Hautarzt       Date:  2021-06-29       Impact factor: 0.751

Review 2.  Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.

Authors:  Michael Zakrewsky; Sunny Kumar; Samir Mitragotri
Journal:  J Control Release       Date:  2015-09-15       Impact factor: 9.776

3.  Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.

Authors:  Ian Gorovoy; Adar Berghoff; Laura Ferris
Journal:  Case Rep Dermatol       Date:  2009-10-27

4.  Increased prevalence of metabolic syndrome in patients with acne inversa.

Authors:  Robert Sabat; Akewit Chanwangpong; Sylke Schneider-Burrus; Deborah Metternich; Georgios Kokolakis; Agata Kurek; Sandra Philipp; Daniela Uribe; Kerstin Wolk; Wolfram Sterry
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 5.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 6.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Authors:  Shi Yu Derek Lim; Hazel H Oon
Journal:  Biologics       Date:  2019-05-13

Review 7.  TNF-α inhibitors in the treatment of hidradenitis suppurativa.

Authors:  Kevin T Savage; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Ther Adv Chronic Dis       Date:  2019-05-27       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.